A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
Sign Up to like & getrecommendations! Published in 2021 at "Biomaterials"
DOI: 10.1016/j.biomaterials.2021.121258
Abstract: Current therapy in acute myeloid leukemia (AML) is based on chemotherapeutic drugs administered at high doses, lacking targeting selectivity and displaying poor therapeutic index because of severe adverse effects. Here, we develop a novel nanoconjugate… read more here.
Keywords: ara prodrug; prodrug; acute myeloid; myeloid leukemia ... See more keywords